Drug profile · INN
burosumab-twza
CRYSVITA
burosumab-twza (CRYSVITA) is a fibroblast growth factor 23 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — burosumab-twza
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
burosumab-twza (CRYSVITA) is a fibroblast growth factor 23 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Fibroblast growth factor 23 inhibitor
Primary target: Fibroblast growth factor 23
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is burosumab-twza?
burosumab-twza (CRYSVITA) is a fibroblast growth factor 23 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for burosumab-twza?
CRYSVITA is a marketed brand name for burosumab-twza. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of burosumab-twza?
burosumab-twza has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.